Erratum: A high aldosterone to renin ratio is associated with high serum parathyroid hormone concentrations in the general population (Journal of Clinical Endocrinology and Metabolism (2014) 99:3 (965-971) DOI: 10.1210/jc.2013-3214);A high aldosterone to renin ratio is associated with high serum parathyroid hormone concentrations in the general population

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 3, 2014, Pages 965-971

  Fischer, Evelyn ^a   Hannemann, Anke ^b   Rettig, Rainer ^b   Lieb, Wolfgang ^b,c   Nauck, Matthias ^b   Pallauf, Anna ^a   Bildingmaier, Martin ^a   Beuschlein, Felix ^a   Wallaschofski, Henri ^b   Reincke, Martin ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALDOSTERONE; PARATHYROID HORMONE; RENIN;

ADULT; AGE DISTRIBUTION; AGED; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE TO RENIN RATIO; ARTICLE; BODY MASS; BONE METABOLISM; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; GERMANY; GLOMERULUS FILTRATION; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; LIVER DISEASE; MALE; MEDICAL PARAMETERS; PARATHYROID HORMONE BLOOD LEVEL; PLASMA RENIN ACTIVITY; POPULATION RESEARCH; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; VITAMIN BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ALDOSTERONE; FEMALE; GERMANY; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; RENIN; RENIN-ANGIOTENSIN SYSTEM; YOUNG ADULT;

EID: 84895793037     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3214     Document Type: Erratum

References (44)

1. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266-3281.
2. Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient's cohorts and in population-based studies - a review of the current literature. Horm Metab Res. 2012;44:157-162.
3. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168:80-85.
4. Fallo F, Pilon C, Urbanet R. Primary aldosteronism and metabolic syndrome. Horm Metab Res. 2012;44:208-214.
5. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248. (Pubitemid 40523144)
6. Reincke M, Fischer E, Gerum S, et al. Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension. 2012;60:618-624.
7. Grant FD, Mandel SJ, Brown EM, Williams GH, Seely EW. Interrelationships between the renin-angiotensin-aldosterone and calcium homeostatic systems. J Clin Endocrinol Metab. 1992;75:988-992.
8. Maniero C, Fassina A, Seccia TM, et al. Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J Hypertens. 2012;30:390-395.
9. Pilz S, Tomaschitz A, Marz W, Cavalier E, Ritz E. Aldosterone and parathyroid hormone: a complex and clinically relevant relationship. Calcif Tissue Int. 2010;87:373-374.
10. Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med. 1985;78:385-390. (Pubitemid 15107917)
11. Pilz S, Kienreich K, Drechsler C, et al. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab. 2012;97:E75-E79.
12. Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens. 1995;8:884-893.
13. Brunaud L, Germain A, Zarnegar R, et al. Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery. 2009;146:1035-1041.
14. Kovacs L, Goth MI, Szabolcs I, Dohan O, Ferencz A, Szilagyi G. The effect of surgical treatment on secondary hyperaldosteronism and relative hyperinsulinemia in primary hyperparathyroidism. Eur J Endocrinol. 1998;138:543-547. (Pubitemid 28238190)
15. Hagstrom E, Hellman P, Larsson TE, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009;119:2765-2771.
16. Hedback GM, Oden AS. Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism. J Intern Med. 2002;251:476-483. (Pubitemid 34537310)
17. Tomaschitz A, Ritz E, Pieske B, et al. Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. Cardiovasc Res. 2012;94:10-19.
18. Volzke H, Alte D, Schmidt CO, et al. Cohort profile: the Study of Health in Pomerania. Int J Epidemiol. 2011;40:294-307.
19. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366:1059-1062. (Pubitemid 41338752)
20. Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:A0828.
21. Stone C, Koo C. Additive Splines in Statistics. Proceedings of the Statistical Computing Section. Washington, DC: American Statistical Association; 1985.
22. Pilz S, Tomaschitz A, Drechsler C, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J. 2010;31:1591-1598.
23. Ozata M, Durmus O, Yilmaz MI, Bolu E, Erdogan M, Ozdemir IC. The renin-angiotensin-aldosterone system (RAAS) and its relation with calcium homeostasis in male obesity. Med Sci Monit. 2002;8:CR430-CR434.
24. Ferriss JB, Brown JJ, Cumming AM, et al. Primary hyperparathyroidism associated with primary hyperaldosteronism. Acta Endocrinol (Copenh). 1983;103:365-370. (Pubitemid 13060439)
25. Maniero C, Fassina A, Guzzardo V, et al. Primary hyperparathyroidism with concurrent primary aldosteronism. Hypertension. 2011;58:341-346.
26. Isales CM, Barrett PQ, Brines M, Bollag W, Rasmussen H. Parathyroid hormone modulates angiotensin II-induced aldosterone secretion from the adrenal glomerulosa cell. Endocrinology. 1991;129:489-495.
27. Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG. PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Endocrinol Metab. 2001;280:E209-E213.
28. Rosenberg J, Pines M, Hurwitz S. Response of adrenal cells to parathyroid hormone stimulation. J Endocrinol. 1987;112:431-437. (Pubitemid 17020880)
29. Barkan A, Marilus R, Winkelsberg G, Yeshurun D, Blum I. Primary hyperparathyroidism: possible cause of primary hyperaldosteronism in a 60-year-old woman. J Clin Endocrinol Metab. 1980;51:144-147. (Pubitemid 10009251)
30. Fertig A, Webley M, Lynn JA. Primary hyperparathyroidism in a patient with Conn's syndrome. Postgrad Med J. 1980;56:45-47. (Pubitemid 10214686)
31. Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, Marz W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J. 2010;31:1237-1247.
32. Anderson JL, Vanwoerkom RC, Horne BD, et al. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Am Heart J. 2011;162:331-339.
33. Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg. 2003;27:216-222. (Pubitemid 36926340)
34. Ogard CG, Sondergaard SB, Vestergaard H, Jakobsen H, Nielsen SL. Myocardial perfusion defects and the left ventricular ejection fraction disclosed by scintigraphy in patients with primary hyperparathyroidism. World J Surg. 2005;29:914-916. (Pubitemid 41804855)
35. Rosenberg J, Pines M, Hurwitz S. Stimulation of chick adrenal steroidogenesis by avian parathyroid hormone. J Endocrinol. 1988;116:91-95. (Pubitemid 18029130)
36. Bernini G, Moretti A, Lonzi S, Bendinelli C, Miccoli P, Salvetti A. Renin-angiotensin-aldosterone system in primary hyperparathyroidism before and after surgery. Metabolism. 1999;48:298-300. (Pubitemid 29115989)
37. Pacifici R, Perry HM 3rd, Shieber W, Biglieri E, Droke DM, Avioli LV. Adrenal responses to subtotal parathyroidectomy for primary hyperparathyroidism. Calcif Tissue Int. 1987;41:119-123.
38. Schiffl H, Lang SM. Hypertension secondary to PHPT: cause or coincidence? Int J Endocrinol. 2011;2011:974647.
39. Salcuni AS, Palmieri S, Carnevale V, et al. Bone involvement in aldosteronism. J Bone Miner Res. 2012;27:2217-2222.
40. Ceccoli L, Ronconi V, Giovannini L, et al. Bone health and aldosterone excess. Osteoporos Int. 2013;24(11):2801-2807.
41. Gupta M, Cheung CL, Hsu YH, et al. Identification of homogeneous genetic architecture of multiple genetically correlated traits by block clustering of genome-wide associations. J Bone Miner Res. 2011;26:1261-1271.
42. Khouzam RN, Dishmon DA, Farah V, Flax SD, Carbone LD, Weber KT. Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure. Am J Med Sci. 2006;331:30-34. (Pubitemid 43177513)
43. van Diepen S, Majumdar SR, Bakal JA, McAlister FA, Ezekowitz JA. Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16 294 patients. Circulation. 2008;118:1946-1952.
44. Paik JM, Curhan GC, Taylor EN. Calcium intake and risk of primary hyperparathyroidism in women: prospective cohort study. BMJ. 2012;345:e6390.